Pet parent guide
How is cancer treatment response monitored in dogs?
A plain-language guide to follow-up care, remission and how molecular residual disease monitoring fits into your dog's veterinary care.
Canos · Published
Monitoring connects one visit to the next
Your dog’s oncology team follows how they feel, how their cancer responds and what changes over time. Examination, imaging, bloodwork and molecular testing each contribute a different view. The follow-up schedule reflects your dog’s cancer and treatment. AAHA follow-up guidance, 2026.
A molecular view of treatment response
Cancer-associated DNA signals in blood can be measured repeatedly. Comparing samples with a starting baseline shows how those signals change during therapy. Canine research has reported changes linked to disease status during treatment and follow-up. Read the longitudinal study, 2026.
Following minimal residual disease
Minimal residual disease (MRD) is cancer that remains after treatment. Molecular monitoring adds information about cancer-associated signals during remission, giving your veterinary team another view between clinical visits.
Keep a dated record of appetite, activity and comfort to share with your vet alongside test results.
How OncoTrack works
Canos OncoTrack tracks molecular residual disease and cancer-associated signals through treatment and follow-up. Establish a baseline, compare samples during treatment, and continue monitoring after treatment.
Canos bioinformatics integrates complementary cfDNA signals across canine cancer studies, including longitudinal data following 117 dogs across 514 time points. Read the Canos bioinformatics preprint, 2026.
Apply for OncoTrack. Our team reviews eligibility and works with you and your vet to arrange sampling. Testing is free for accepted dogs.
For general information. Your veterinarian can help interpret what applies to your dog.